CSF2 and melanoma: In particular, the phase III trial of T-VEC (genetically modified herpes simplex virus expressing GM-CSF) demonstrated improvements in durable response rate and a trend toward improved overall survival compared to GM-CSF alone, which led to the approval by the FDA of its use in advanced melanoma patients [17].